Download PDF
Semin Respir Crit Care Med 2017; 38(03): 301-310
DOI: 10.1055/s-0037-1602656
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?

Matteo Bassetti
1   Infectious Disesaes Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Udine, Italy
,
Maddalena Peghin
1   Infectious Disesaes Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Udine, Italy
,
Alessia Carnelutti
1   Infectious Disesaes Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Udine, Italy
,
Elda Righi
1   Infectious Disesaes Clinic, Department of Medicine University of Udine and Santa Maria Misericordia Hospital, Udine, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2017 (online)

    Permissions and Reprints

Abstract

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent a common problem in hospital setting worldwide. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are an emergent problem due to the lack of therapeutic options available, leading to significant increases in morbidity and mortality. CRE have frequently been reported both in HAP/VAP, but limited data regarding the optimal treatment strategy in this setting are available. This review focuses on the current epidemiology of CRE, with a specific focus on HAP/VAP. Moreover, we will suggest a possible strategy for the empiric and targeted treatment of HAP and VAP in which the involvement of CRE is suspected or is confirmed.

Keywords

hospital-acquired pneumonia - ventilator-acquired pneumonia - carbapenemase-producing Enterobacteriaceae - antibiotic therapy - multidrug-resistant gram negative
 

  • References

  • 1 Kalil AC, Metersky ML, Klompas M. , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
    CrossrefPubMedGoogle Scholar
  • 2 Magill SS, Edwards JR, Fridkin SK. ; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Survey of health care-associated infections. N Engl J Med 2014; 370 (26) 2542-2543
    CrossrefPubMedGoogle Scholar
  • 3 Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19 (03) 216-228
    CrossrefPubMedGoogle Scholar
  • 4 Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10 (05) 585-596
    CrossrefPubMedGoogle Scholar
  • 5 Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014; 6 (02) 134-142
    PubMedGoogle Scholar
  • 6 Quartin AA, Scerpella EG, Puttagunta S, Kett DH. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 2013; 13: 561
    CrossrefPubMedGoogle Scholar
  • 7 Herkel T, Uvizl R, Doubravska L. , et al. Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160 (03) 448-455
    CrossrefPubMedGoogle Scholar
  • 8 Delle Rose D, Pezzotti P, Fortunato E. , et al. Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals. Eur J Clin Microbiol Infect Dis 2016; 35 (09) 1531-1539
    CrossrefPubMedGoogle Scholar
  • 9 Tumbarello M, Viale P, Viscoli C. , et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55 (07) 943-950
    CrossrefPubMedGoogle Scholar
  • 10 Pea F, Della Siega P, Cojutti P. , et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. Int J Antimicrob Agents 2017; 49 (02) 255-258
    CrossrefPubMedGoogle Scholar
  • 11 Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant enterobacteriaceae (CRE)–November 2015 update CRE toolkit. Available at: https://www.cdc.gov/hai/organisms/cre/cre-toolkit/ . Accessed April 14, 2017
    PubMedGoogle Scholar
  • 12 van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2016; 11: 1-10
    PubMedGoogle Scholar
  • 13 The European Committee on Antimicrobial Susceptibility Testing. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Available at: http://www.eucast.org/resistance_mechanisms/ . Accessed April 14, 2017
    PubMedGoogle Scholar
  • 14 Center for Disease Dynamics, Economics & Policy. Available at: http://www.cddep.org . Accessed April 14, 2017
    PubMed
  • 15 Centers for Diseases Control and Prevention. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf . Accessed April 14, 2017
    PubMed
  • 16 Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL. ; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015; 20 (45) 1-6
    PubMedGoogle Scholar
  • 17 The European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2014. Available at: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf
    PubMedGoogle Scholar
  • 18 Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; S0924-8579(17)30032-8
    PubMedGoogle Scholar
  • 19 Capone A, Giannella M, Fortini D. , et al; SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19 (01) E23-E30
    CrossrefPubMedGoogle Scholar
  • 20 Giacobbe DR, Del Bono V, Trecarichi EM. , et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21 (12) 1106.e1-1106.e8
    CrossrefPubMedGoogle Scholar
  • 21 de Maio Carrilho CM, de Oliveira LM, Gaudereto J. , et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 2016; 16 (01) 629
    CrossrefPubMedGoogle Scholar
  • 22 Wang Q, Zhang Y, Yao X. , et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016; 35 (10) 1679-1689
    CrossrefPubMedGoogle Scholar
  • 23 Qureshi ZA, Paterson DL, Potoski BA. , et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56 (04) 2108-2113
    CrossrefPubMedGoogle Scholar
  • 24 European Centre for Disease Prevention and Control. Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. Stockholm: ECDC; 2011. Available at: http://ecdc.europa.eu/en/publications/Publications/110913_Risk_assessment_resistant_CPE.pdf . Assessed April 14, 2017
    PubMedGoogle Scholar
  • 25 Tuon FF, Rocha JL, Toledo P. , et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis 2012; 16 (05) 416-419
    CrossrefPubMedGoogle Scholar
  • 26 da Silva KE, Maciel WG, Sacchi FP. , et al. Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery. J Med Microbiol 2016; 65 (06) 547-553
    CrossrefPubMedGoogle Scholar
  • 27 Mouloudi E, Protonotariou E, Zagorianou A. , et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31 (12) 1250-1256
    CrossrefPubMedGoogle Scholar
  • 28 Tumbarello M, Trecarichi EM, Tumietto F. , et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58 (06) 3514-3520
    CrossrefPubMedGoogle Scholar
  • 29 Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29 (12) 1099-1106
    CrossrefPubMedGoogle Scholar
  • 30 Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30 (07) 666-671
    CrossrefPubMedGoogle Scholar
  • 31 Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165 (07) 867-903
    CrossrefPubMedGoogle Scholar
  • 32 Chastre J. Conference summary: ventilator-associated pneumonia. Respir Care 2005; 50 (07) 975-983
    PubMedGoogle Scholar
  • 33 Bassetti M, Welte T, Wunderink RG. Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. Crit Care 2016; 20: 19
    PubMedGoogle Scholar
  • 34 Garnacho-Montero J, Corcia-Palomo Y, Amaya-Villar R, Martin-Villen L. How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis 2014; 14: 135
    CrossrefPubMedGoogle Scholar
  • 35 Rosso-Fernández C, Garnacho-Montero J, Antonelli M, Dimopoulos G, Cisneros JM. ; MagicBullet study group Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials 2015; 16: 102
    CrossrefPubMedGoogle Scholar
  • 36 Tumbarello M, Trecarichi EM, De Rosa FG. , et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70 (07) 2133-2143
    CrossrefPubMedGoogle Scholar
  • 37 Daikos GL, Tsaousi S, Tzouvelekis LS. , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (04) 2322-2328
    CrossrefPubMedGoogle Scholar
  • 38 Liapikou A, Torres A. Emerging drugs for nosocomial pneumonia. Expert Opin Emerg Drugs 2016; 21 (03) 331-341
    CrossrefPubMedGoogle Scholar
  • 39 Wunderink RG. Point: Should inhaled antibiotic therapy be routinely used for the treatment of bacterial lower respiratory tract infections in the ICU setting? Yes. Chest 2017; 151 (04) 737-739
    CrossrefPubMedGoogle Scholar
  • 40 Viaggi B, Sbrana F, Malacarne P, Tascini C. Ventilator-associated pneumonia caused by colistin-resistant KPC-producing Klebsiella pneumoniae: a case report and literature review. Respir Investig 2015; 53 (03) 124-128
    CrossrefPubMedGoogle Scholar
  • 41 Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15 (11) e732-e739
    CrossrefPubMedGoogle Scholar
  • 42 Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med 2015; 36 (01) 74-84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?. Expert Opin Pharmacother 2016; 17 (06) 761-781
    CrossrefPubMedGoogle Scholar
  • 44 Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58 (02) 654-663
    CrossrefPubMedGoogle Scholar
  • 45 Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40 (02) 219-223
    CrossrefPubMedGoogle Scholar
  • 46 Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56 (04) 2129-2131
    CrossrefPubMedGoogle Scholar
  • 47 Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2017
    PubMedGoogle Scholar
  • 48 Oliva A, Scorzolini L, Castaldi D. , et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect 2017; 74 (01) 103-106
    CrossrefPubMedGoogle Scholar
  • 49 Cprek JB, Gallagher JC. Ertapenem- containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 60 (01) 669-673
    PubMedGoogle Scholar
  • 50 Rizek C, Ferraz JR, van der Heijden IM. , et al. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. J Infect Chemother 2015; 21 (02) 114-117
    CrossrefPubMedGoogle Scholar
  • 51 Kallel H, Hergafi L, Bahloul M. , et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33 (07) 1162-1167
    CrossrefPubMedGoogle Scholar
  • 52 Imberti R, Cusato M, Villani P. , et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138 (06) 1333-1339
    CrossrefPubMedGoogle Scholar
  • 53 Plachouras D, Karvanen M, Friberg LE. , et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (08) 3430-3436
    CrossrefPubMedGoogle Scholar
  • 54 Gaibani P, Lombardo D, Lewis RE. , et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 2014; 69 (07) 1856-1865
    CrossrefPubMedGoogle Scholar
  • 55 Freire AT, Melnyk V, Kim MJ. , et al; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68 (02) 140-151
    CrossrefPubMedGoogle Scholar
  • 56 Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009; 34 (01) 101-102
    CrossrefPubMedGoogle Scholar
  • 57 Poulakou G, Bassetti M, Righi E, Dimopoulos G. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol 2014; 9 (09) 1053-1069
    CrossrefPubMedGoogle Scholar
  • 58 Bassetti M, De Waele JJ, Eggimann P. , et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 2015; 41 (05) 776-795
    CrossrefPubMedGoogle Scholar
  • 59 Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128 (02) 545-552
    CrossrefPubMedGoogle Scholar
  • 60 Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. Antimicrob Agents Chemother 2017
    PubMedGoogle Scholar
  • 61 Pontikis K, Karaiskos I, Bastani S. , et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43 (01) 52-59
    CrossrefPubMedGoogle Scholar
  • 62 Vasoo S, Cunningham SA, Cole NC. , et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 2015; 59 (12) 7842-7846
    CrossrefPubMedGoogle Scholar
  • 63 Bassetti M, Righi E, Carnelutti A. New therapeutic options for respiratory tract infections. Curr Opin Infect Dis 2016; 29 (02) 178-186
    CrossrefPubMedGoogle Scholar
  • 64 Sader HS, Castanheira M, Flamm RK. Antimicrobial activity of ceftazidime-avibactam when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). Antimicrob Agents Chemother 2017; AAC.02083-16
    PubMedGoogle Scholar
  • 65 Temkin E, Torre-Cisneros J, Beovic B. , et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61 (02) e01964-e02016
    PubMedGoogle Scholar
  • 66 Shields RK, Potoski BA, Haidar G. , et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis 2016; 63 (12) 1615-1618
    CrossrefPubMedGoogle Scholar
  • 67 Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β- lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother 2016; 60 (09) 5454-5458
    CrossrefPubMedGoogle Scholar
  • 68 Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care 2016; 6 (01) 35
    CrossrefPubMedGoogle Scholar
  • 69 Solé-Lleonart C, Rouby JJ, Blot S. , et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology 2017
    PubMedGoogle Scholar
  • 70 Solé-Lleonart C, Roberts JA, Chastre J. , et al; ESGCIP Investigators. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect 2016; 22 (04) 359-364
    CrossrefPubMedGoogle Scholar
  • 71 Chastre J, Wolff M, Fagon JY. , et al; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290 (19) 2588-2598
    CrossrefPubMedGoogle Scholar
  • 72 Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144 (06) 1759-1767
    CrossrefPubMedGoogle Scholar
  • 73 Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care 2013; 19 (05) 453-460
    CrossrefPubMedGoogle Scholar
  • 74 Stolz D, Smyrnios N, Eggimann P. , et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34 (06) 1364-1375
    CrossrefPubMedGoogle Scholar